Why the study?
The pros and cons of icosapent ethyl for the management of hypertriglyceridaemia and practical considerations for its clinical use warranted review.
Does icosapent ethyl improve cardiovascular outcomes in subjects with hypertriglyceridaemia?
Does icosapent ethyl improve cardiovascular outcomes in subjects with hypertriglyceridaemia?
This review summarizes the pros and cons of icosapent ethyl for managing hypertriglyceridaemia and its impact on cardiovascular outcomes based on three major clinical trials.
Evidence on icosapent ethyl remains mixed; leaves open optimal patient selection and net benefit in hypertriglyceridaemia.
Icosapent ethyl (IPE) for hypertriglyceridaemia—what are the pros and cons? In this graphical abstract, we highlight the pros and cons of IPE for the management of hypertriglyceridaemia, discuss the key results of three major clinical trials exploring the role of IPE or eicosapentaenoic acid on cardiovascular outcomes in subjects with hypertriglyceridaemia, and summarize practical considerations for clinicians considering IPE use in practice.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: